Serum betatrophin and irisin levels in hepatocellular carcinoma.
Rattachement africain : pl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Hepatocellular carcinoma (HCC) development is a complex process with well-known risk factors, however the role of betatrophin/angiopoietin-like protein 8 and irisin has been poorly investigated thus far. The aim of this study is to measure betatrophin and irisin serum levels in HCC, cirrhotic patients and controls, assess their relationship with cancer etiology and grade, metabolic abnormalities and liver dysfunction severity. Serum betatrophin and irisin concentrations were measured with commercially available ELISA kits in 69 cirrhotic patients with HCC, 24 patients with non-viral cirrhosis and 20 healthy volunteers. The severity of liver disfunction was assessed according to Child-Pugh (C-P) score, while HCC grade according to the Barcelona clinic liver cancer (BCLC) staging system. Serum betatrophin concentration was significantly higher (33.7 ± 13.4 versus 12.3 ± 2.0 ng/ml; P < 0.001), while serum irisin level significantly lower in HCC patients compared to controls (2.52 ± 1.14 versus 4.46 ± 1.34 μg/ml; P = 0.02). Betatrophin level was also significantly elevated among cirrhotic patients compared to healthy volunteers. More evident serum betatrophin increase was found in patients with viral disease (34.8 ± 12.9 versus 26.1 ± 13.8 ng/ml; P < 0.001). Serum irisin concentration was significantly decreased in more advanced HCC cases (stage A versus C according to BCLC: 3.4 ± 1.3 versus 1.89 ± 1.1 μg/ml; P = 0.02). Decline of serum irisin (A: 3.4 ± 1.2; B: 2.42 ± 0.8; C: 1.91 ± 1.19 μg/ml; P = 0.03) and up-regulation of serum betatrophin levels (A: 24.1 ± 13.8; B: 39.3 ± 11.4; C: 46.2 ± 9.4 ng/ml; P = 0.03) were observed in patients with more advanced cirrhosis according to C-P score. We concluded that betatrophin serum level increased in cirrhotic patients, compared to controls. Since there was no difference between cirrhotic patients with and without intercurrent HCC, we suppose it may have an influence on fibrosis development, however not hepatocarcinogensis. Irisin serum level decreased in HCC patients, especially with more advanced disease grade, and was inversely related to the severity of liver disfunction.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Wroclaw Medical University Department of Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Wroclaw Research Centre EIT+ (Poland) pays non établi dans la noticeEntreprise
-
Łukasiewicz Research Network – PORT Polish Center for Technology Development pays non établi dans la noticeStructure de recherche
-
Medical University of Silesia Department of Digestive Tract Surgery pays non établi dans la noticeUniversité ou école supérieure
-
University of Silesia in Katowice pays non établi dans la noticeUniversité ou école supérieure
-
Jagiellonian University Department of Internal Medicine and Geriatrics pays non établi dans la noticeUniversité ou école supérieure
-
Cracow University of Technology pays non établi dans la noticeUniversité ou école supérieure
-
Regional Specialistic Hospital in Wroclaw Department of Infectious Diseases pays non établi dans la noticeÉtablissement de santé
-
University Hospital in Cracow Department of Endoscopy pays non établi dans la noticeUniversité ou école supérieure
Department of Infectious Diseases — Wroclaw Medical University, Wroclaw Research Centre EIT+ (Poland) et Łukasiewicz Research Network – PORT Polish Center for Technology Development, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.